Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
It is incredulous that AEZS remains at a $125M market cap.
With so many late stage products in development and so much in the pipeline, this looks to me as 5X to 10X bagger laying in wait.
A
